The U.S. FDA has approved the use of Pfizer's BRAFTOVI® combination therapy as a first-line treatment for metastatic colorectal cancer with BRAF V600E mutations.

Vertex has received US FDA approval for ALYFTREK™, a new once-daily CFTR modulator aimed at treating cystic fibrosis.

the Antibody-Drug Conjugates (ADCs) market has entered a new phase of rapid growth since 2019, maintaining an annual growth rate exceeding 30%.

Marengo has dosed its initial patient in the Phase 2 clinical trial of Invikafusp Alfa (STAR0602) targeting PD-1 resistant tumors and is extending the study to Europe.

JCR Pharmaceuticals launches Phase III trial for JR-142 in Japan, a long-lasting growth hormone treatment.

Merck signs exclusive global licensing deal for LM-299, a candidate bispecific antibody targeting PD-1 and VEGF.

InflaRx reports the initial patient has been treated in the Phase 2a trial for the oral C5aR inhibitor INF904.

Novo Nordisk A/S: In the REDEFINE 1 trial, CagriSema shows better weight loss results for adults with obesity or excess weight.

Oruka Therapeutics reports that the initial participants have received doses in the Phase 1 trial of ORKA-001, a new antibody that extends half-life and targets IL-23p19.

Regeneron will move forward with two Factor XI antibodies into an extensive Phase 3 program after successful Phase 2 proof-of-concept outcomes.

Vittoria Biotherapeutics has commenced dosing the initial patient in the Phase 1 clinical trial for VIPER-101.

TRYNGOLZA™ (olezarsen) has received U.S. approval as the first treatment for adults with familial chylomicronemia syndrome, used alongside dietary changes.